ERBB2 and breast cancer: The immunohistochemical tests establish the absence of receptors for estrogen, progesterone, the absence / the presence of HER2 gene and the increased levels of cathepsins D in breast cancer estrogen and the progesterone (-), being a feature that can be targeted in gene therapy [4].